Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors.
Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors.
复制标题
人类肿瘤中血管生成表型自发回复为非血管生成和休眠状态。
DOI：
10.1158/1541-7786.mcr-13-0532-t
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
Rogers,MichaelS;Novak,Katherine;Zurakowski,David;Cryan,LornaM;Blois,Anna;Lifshits,Eugene;Bø,TrondH;Oyan,AnneM;Bender,EliseR;Lampa,Michael;Kang,Soo-Young;Naxerova,Kamila;Kalland,Karl-Henning;Straume,Oddbjorn;Akslen,LarsA;
The angiogenic switch, a rate-limiting step in tumor progression, has already occurred by the time most human tumors are detectable. However, despite significant study of the mechanisms controlling this switch, the kinetics and reversibility of the process have not been explored. The stability of the angiogenic phenotype was examined using an established human liposarcoma xenograft model. Nonangiogenic cells inoculated into immunocompromised mice formed microscopic tumors that remained dormant for approximately 125 days (vs. <40 days for angiogenic cells) whereupon the vast majority (>95%) initiated angiogenic growth with second-order kinetics. These original, clonally derived angiogenic tumor cells were passaged through fourin vivocycles. At each cycle, a new set of single-cell clones was established from the most angiogenic clone and characterized forin vivofor tumorigenic activity. A total of 132 single-cell clones were tested in the second, third, and fourthin vivopassage. Strikingly, at each passage, a portion of the single-cell clones formed microscopic, dormant tumors. Following dormancy, like the original cell line, these revertant tumors spontaneously switched to the angiogenic phenotype. Finally, revertant clones were transcriptionally profiled and their angiogenic output determined. Collectively, these data demonstrate that the angiogenic phenotype in tumors is malleable and can spontaneously revert to the nonangiogenic phenotype in a population of human tumor cells.Implications:Leveraging the rate of reversion to the nonangiogenic phenotype and tumor dormancy may be a novel anticancer strategy.Mol Cancer Res; 12(5); 754–64. ©2014 AACR.
